These results show that use of an optimized p53 IHC assay is an accurate predictor of the presence and class of TP53 mutations in ovarian carcinoma with high specificity and sensitivity for prediction of GOF mutations and NDM status. This evidence concerns the gene TP53 and ovarian carcinoma.